PA8795701A1 - Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 - Google Patents

Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3

Info

Publication number
PA8795701A1
PA8795701A1 PA20088795701A PA8795701A PA8795701A1 PA 8795701 A1 PA8795701 A1 PA 8795701A1 PA 20088795701 A PA20088795701 A PA 20088795701A PA 8795701 A PA8795701 A PA 8795701A PA 8795701 A1 PA8795701 A1 PA 8795701A1
Authority
PA
Panama
Prior art keywords
histamine
isoquinolinilo
isoindolinilo
antagonists
derivatives
Prior art date
Application number
PA20088795701A
Other languages
English (en)
Inventor
Dahui Zhou
Jonathan Laird Gross
Albert Jean Robichaud
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8795701A1 publication Critical patent/PA8795701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA I Y EL USO DE ÉSTE PARA EL TRATAMIENTO DE UN TRASTORNO DEL SISTEMA NERVIOSOS CENTRAL RELACIONADO CON O AFECTADO POR EL RECEPTOR DE HISTAMINA -3.
PA20088795701A 2007-09-12 2008-09-12 Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 PA8795701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12

Publications (1)

Publication Number Publication Date
PA8795701A1 true PA8795701A1 (es) 2009-04-23

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088795701A PA8795701A1 (es) 2007-09-12 2008-09-12 Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3

Country Status (25)

Country Link
US (1) US20090069300A1 (es)
EP (1) EP2200989A1 (es)
JP (1) JP2010539180A (es)
KR (1) KR20100054856A (es)
CN (1) CN101848896A (es)
AP (1) AP2010005202A0 (es)
AR (1) AR068423A1 (es)
AU (1) AU2008298926A1 (es)
BR (1) BRPI0817061A2 (es)
CA (1) CA2699384A1 (es)
CL (1) CL2008002726A1 (es)
CO (1) CO6300955A2 (es)
CR (1) CR11303A (es)
DO (1) DOP2010000079A (es)
EA (1) EA201000316A1 (es)
EC (1) ECSP10010025A (es)
MA (1) MA31699B1 (es)
MX (1) MX2010002760A (es)
NI (1) NI201000036A (es)
PA (1) PA8795701A1 (es)
PE (1) PE20090651A1 (es)
TN (1) TN2010000105A1 (es)
TW (1) TW200927114A (es)
WO (1) WO2009036144A1 (es)
ZA (1) ZA201001751B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
HUE034911T2 (hu) * 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
EP2632461A4 (en) * 2010-10-29 2014-04-02 Merck Sharp & Dohme ISOINDOLINONE COMPOUNDS USEFUL AS PDE INHIBITORS 10
US9115096B2 (en) * 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
WO2013004652A1 (de) 2011-07-04 2013-01-10 Bayer Intellectual Property Gmbh Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2013076590A1 (en) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
EP4132646A1 (en) * 2020-04-08 2023-02-15 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4203952A1 (en) * 2020-08-28 2023-07-05 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP2001523256A (ja) * 1997-05-01 2001-11-20 イーライ・リリー・アンド・カンパニー 抗血栓物質
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
AR042423A1 (es) * 2002-09-19 2005-06-22 Lilly Co Eli Diaril eteres como antagonistas del receptor opioide
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101107231A (zh) * 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
EP1877401A2 (en) * 2005-04-15 2008-01-16 Elan Pharmaceuticals Inc. Novel compounds useful for bradykinin b1 receptor antagonism

Also Published As

Publication number Publication date
US20090069300A1 (en) 2009-03-12
WO2009036144A1 (en) 2009-03-19
CO6300955A2 (es) 2011-07-21
TW200927114A (en) 2009-07-01
AP2010005202A0 (en) 2010-04-30
MX2010002760A (es) 2010-04-01
EA201000316A1 (ru) 2010-10-29
KR20100054856A (ko) 2010-05-25
CN101848896A (zh) 2010-09-29
TN2010000105A1 (fr) 2011-09-26
CA2699384A1 (en) 2009-03-19
CL2008002726A1 (es) 2008-10-10
CR11303A (es) 2010-03-18
MA31699B1 (fr) 2010-09-01
DOP2010000079A (es) 2010-03-31
JP2010539180A (ja) 2010-12-16
PE20090651A1 (es) 2009-05-28
AU2008298926A1 (en) 2009-03-19
ZA201001751B (en) 2010-11-24
ECSP10010025A (es) 2010-08-31
AR068423A1 (es) 2009-11-18
EP2200989A1 (en) 2010-06-30
BRPI0817061A2 (pt) 2015-03-24
NI201000036A (es) 2010-08-13

Similar Documents

Publication Publication Date Title
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CU20100159A7 (es) Compuestos
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CL2016001348A1 (es) Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos